NK cell companies agree they differ, but not on what features matter most

It’s been a challenging few months on the NK cell therapy rollercoaster, but executives are making the case that setbacks affecting one program don’t read through to others. 

Differences in the sources of the cells, the ways the cells are modified, their manufacturing protocols and their dosing strategies will all impact clinical performance, executives from six NK cell companies told BioCentury. ...